The gist of it
The Q2 2026 10-Q shows Supernus growing revenue at its fastest pace in years while simultaneously reporting a GAAP operating loss. Those two facts coexist because a single write-down on an aging drug swamped an otherwise improving business. The stock sits well below its 52-week high, priced as if the loss is the story. The filed numbers suggest the write-down was a one-time event, but a pending merger with Indivior means the company a buyer is pricing today may not exist in its current form by year-end.
A company built on acquisitions, now betting on another
Supernus spent most of the 2010s as a tidy two-drug epilepsy franchise. Then, starting in 2020, it went shopping. It bought a Parkinson’s portfolio from US WorldMeds, acquired Adamas Pharmaceuticals to add GOCOVRI, and in June 2025 completed the purchase of Sage Therapeutics, folding in ZURZUVAE, a treatment for postpartum depression. Each deal added revenue and debt in roughly equal measure, which is why the company’s net margin swung from solidly positive to negative by FY2025, per our data computed from SEC filings. The business grew; the earnings got complicated.
Now comes the largest bet yet. On August 3, 2026, Supernus announced an all-stock merger with Indivior Pharmaceuticals, the addiction-medicine specialist, projecting a combined entity with roughly $2.2 billion in annual revenue and $125 million in annual cost savings. To fund a large cash dividend to Indivior shareholders, the combined company plans to take on significant new bank debt, leaving a projected net debt load of $878 million post-close. That is a meaningful obligation for a business currently earning near breakeven on a GAAP basis.
What the quarter actually showed
Strip out the noise and Q2 2026 was a strong operating quarter. Total revenues reached $219.1 million, up 32% from the same period a year earlier. Qelbree, the ADHD drug approved for children in 2021 and adults in 2022, generated $89.2 million in net sales as prescriptions climbed strongly, with volume up roughly one-sixth year over year. ZURZUVAE contributed meaningful collaboration revenue. ONAPGO, the subcutaneous Parkinson’s infusion that received FDA approval in September 2026 and began reaching patients in Q2 2025, is an early but growing contributor. Together, the growth products generated $175.7 million, a 52% increase from a year ago.
The GAAP operating loss came almost entirely from one line: a $54.9 million impairment charge on Apokyn, an older injectable Parkinson’s drug that has faced generic competition since the FTC sided against Supernus in March 2023. An impairment charge is an accounting acknowledgment that an asset is worth less than the company originally paid for it. It is a real cost in the sense that the original capital is gone, but it does not consume cash in the quarter it is recorded. The underlying business, before that write-down, was operating closer to breakeven on a GAAP basis and generating cash, as evidenced by the company’s cash balance rising meaningfully between year-end 2025 and June 30, 2026.
What compounds from here
Two things are building quietly. First, Qelbree’s prescription trajectory: a double-digit volume gain in a single quarter, in a market where payer pushback on ADHD drugs is a documented concern raised on earnings calls, suggests the drug is still in its commercial growth phase rather than plateauing. Second, ONAPGO is early. At $13.5 million as it moves through its second year of availability, it is a small contributor today, but Supernus is working to add a second manufacturing supplier, with an FDA submission expected in Q3 2026 and potential approval by mid-2027. Supply constraints on a novel infusion device are a real ceiling; removing them matters.
The pipeline behind those products carries meaningful risk. SPN-820 for depression and SPN-817 for epilepsy are both in Phase 2b trials, meaning they are years from any revenue contribution and carry the usual clinical failure odds. SPN-820 already failed one Phase 2b endpoint in February 2025 before the current trial design was revised. Phase 2b is the stage where a drug proves it works well enough to justify the expensive Phase 3 trial that precedes FDA review; most candidates do not make it through.
Strip out the noise and the filed fundamentals show a business growing revenue briskly with a balance sheet that is generating cash. The market’s current pricing reflects a stock well off its highs, apparently incorporating merger uncertainty, debt risk, and the memory of last year’s negative earnings. Whether those two readings reconcile depends almost entirely on whether the Indivior merger closes as structured and whether the combined debt load stays manageable, data that is not yet available.
Reading the numbers
- $219.1 million in Q2 2026 revenue (filed in the 10-Q for the quarter ended June 30, 2026). This is total revenue for one quarter. At this run rate, the full year would approach $860 million, consistent with the raised guidance range of $860 million to $890 million. Think of it as the company billing roughly $2.4 million every single day.
- $54.9 million impairment charge on Apokyn. An impairment is the accounting equivalent of admitting a purchase was overpriced. The company paid for Apokyn expecting future profits; generic competition reduced those profits, so the asset’s carrying value had to be written down. This charge is why the GAAP operating loss looks alarming. It does not mean $54.9 million left the bank account in Q2.
- $372 million in cash as of June 30, 2026, against $40 million in current debt. That is roughly nine times the debt in liquid assets, a comfortable cushion before the merger closes. A household analogy: owing $400 on a credit card while holding $3,700 in a checking account.
- P/E of 34.6 vs. a decade median of 31.4 (our data). The price-to-earnings multiple is the price tag per dollar of annual profit. At 34.6, the market is paying slightly above Supernus’s own historical average, which is notable given that GAAP earnings are currently negative. The market is effectively pricing a recovery in earnings, not the current loss.
- 73% gross profit margin as of the trailing 12 months through June 2026. For every dollar of product revenue, Supernus keeps 73 cents after manufacturing costs. That is typical for branded pharmaceuticals and means the business has significant room to cover R&D and overhead if revenue keeps growing.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- Supernus Q2 2026 earnings release (GlobeNewswire, August 3, 2026)
- Supernus-Indivior merger announcement (BioSpace)
- FDA approval of ONAPGO (AHDB Online)
- Supernus Q1 2026 earnings call transcript (Motley Fool)
- Supernus Q1 2026 earnings call transcript (Investing.com)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
